ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
A Curcumin-Modified Coordination Polymers with ROS Scavenging and Macrophage Phenotype Regulating Properties for Efficient Ulcerative Colitis Treatment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Structural and temporal dynamics of nano-based therapies in ulcerative colitis: history, hotspots, and emerging trends.Frontiers in immunology · 2026Pooled it
- Triptolide loaded cerium oxide nanozyme based oral nanoplatform for targeted colitis therapy.International journal of pharmaceutics: X · 2026Article
- A closed-loop myocardial infarction theranostic platform activated by macrophage-derived nitric oxide and acidic microenvironment.Bioactive materials · 2026Article
- Intelligent microneedle patch with cobalt-iron Prussian blue nanozymes for accelerating diabetic wound healingBioactive materials · 2026Article
- Curcumin in ischemia-reperfusion injury across multiple organs: A review.The Journal of international medical research · 2026Review
- Cardiac-targeting peptide-modified Prussian blue nanozymes loaded with Astragaloside IV for efficient ICI-myocarditis therapy.Materials today. Bio · 2026Article
- An inhalable nanozyme for STING blockade to treat radiation-induced lung injury.Journal of nanobiotechnology · 2026Article
- Metal-Organic Framework as Contrast Agents for Magnetic Resonance Imaging.Pharmaceutics · 2026Review
- Advances in single-cell surface engineering: nano-coating and core-shell strategies for probiotics delivery in inflammatory bowel disease.Archives of microbiology · 2026Review
- Targeting IBD treatment: smart drug delivery systems for oral administration.Materials today. Bio · 2026Review
- Directional Liquid Transport Enabled pH-Responsive Hierarchical Composite for Enhanced Wound Healing.Advanced healthcare materials · 2026Article
- Neutrophil-mediated delivery of curcumin-loaded manganese-doped zeolitic imidazolate framework-8 nanozymes for pulmonary arterial hypertension.Journal of nanobiotechnology · 2026Article
- Construction of a nanozyme composite drug delivery system based on columbianadin for inflammatory bowel disease therapy.RSC advances · 2026Article
- DFT-Guided Design of a Multi-Enzyme Mimetic High-Entropy Nanozyme for Cascaded Glutathione Detection and Point-of-Care Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- UltrafastMaterials today. Bio · 2025Article
- Polydopamine Nanodots Ameliorate Inflammatory Bowel Disease by Restoring Redox Homeostasis and Intestinal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Synergetic regulation of osteoimmune microenvironment and osteogenesis by decellularized amnion membrane for guided bone regeneration.Materials today. Bio · 2025Article
- Bridging MOF properties to 3D printing: a framework for electrochemical energy storage architectures with synergistic porosity-ion dynamics.Chemical science · 2025Review
- New advances of nanozymes for the diagnosis and treatment of digestive system diseases (Review).International journal of molecular medicine · 2025Review
- Curcumin for inflammatory bowel disease therapy: advances in mechanisms, clinical applications, and drug delivery.Archives of pharmacal research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
Overexpression of classically activated macrophages (M1) subtypes and assessed reactive oxygen species (ROS) levels are often observed in patients with ulcerative colitis. At present, the treatment system of these two problems has yet to be established. Here, the chemotherapy drug curcumin (CCM) is decorated with Prussian blue analogs in a straightforward and cost-saving manner. Modified CCM can be released in inflammatory tissue (acidic environment), eventually causing M1 macrophages to transform into M2 macrophages and inhibiting pro-inflammatory factors. Co(III) and Fe(II) have abundant valence variations, and the lower REDOX potential in CCM-CoFe PBA enables ROS clearance through multi-nanomase activity. In addition, CCM-CoFe PBA effectively alleviated the symptoms of UC mice induced by DSS and inhibited the progression of the disease. Therefore, the present material may be used as a new therapeutic agent for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.